Commentary|Videos|September 12, 2024
Utilizing Global Proteomics and Biomarker Research to Advance Alzheimer Precision Medicine: Fiona Elwood, PhD
Author(s)Fiona Elwood, PhD
The disease area stronghold leader in neurodegeneration at Johnson & Johnson provided insight on the importance of the Global Neurodegeneration Proteomics Consortium, illustrated in several presentations at the recently concluded AAIC 2024. [WATCH TIME: 7 minutes]
Advertisement
WATCH TIME: 7 minutes
"We’ve identified three distinct subtypes of Alzheimer’s disease that align with different core biology based on the types of proteins that are dysregulated."
Even as the knowledge profile of Alzheimer disease (AD) continues to grow, there are still unknown molecular aspects of the pathogenesis of the disease. In recent years, the number of proteomic studies that examine the protein changes in AD brain tissue has been increasing.
At the recently concluded 2024 Alzheimer’s Association International Conference (AAIC) , held July 28-August 1, investigators from Johnson & Johnson presented a large-scale analysis of protein changes associated with neurodegenerative disorders using data from the Global Neurodegeneration Proteomics Consortium (GNPC). The presentations showcased research validated the phosphorylated tau (p-tau)217 assay across various global patient cohorts to assess its performance beyond clinical trial populations.
The 2 abstracts also covered data that identified 3 distinct subtypes based on proteomic fingerprints. The research, supported by multiple global studies, suggests that AD can be staged and subtyped more accurately, leading to more personalized strategies. Following the meeting, Fiona Elwood, PhD, disease area stronghold leader in neurodegeneration at Johnson & Johnson, sat down to discuss the GNPC and the supportive data presented at AAIC 2024.
In the conversation, Elwood highlights recent advances in understanding AD pathology, specifically through proteomics and the identification of tau protein fragments. In addition, she described the significance of shift from postmortem pathology to PET imaging and now to blood-based biomarkers. Overall, Elwood stressed that there is potential to treat patients more precisely through individual biological profiles.
REFERENCES
1. Smets B, Khan A, Greene J, et al. Large-scale proteomics to enable precision medicine for Alzheimer disease. Presented at: Alzheimer’s Association International Conference; July 28-August 1, 2024; Philadelphia, PA.
2. Gargas T, Hou L, Wrzesinski T, et al. Identification of cross-diagnostic protein signatures and subtypes of neurodegenerative diseases using multi-task deep learning on the UK Biobank proteomics dataset. Presented at: Alzheimer’s Association International Conference; July 28-August 1, 2024; Philadelphia, PA.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Related Articles
- 2025 Women in Neurology Conference: Educating, Mentoring, and Networking
September 15th 2025
- This Week on NeurologyLive® — September 15, 2025
September 15th 2025
- NeurologyLive® Brain Games: September 14, 2025
September 14th 2025
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive
1
MDA and PPMD Release Consensus Guidelines for Safe and Equitable Use of Gene Therapy in Duchenne
2
10 Years of the Women Neurologists Group: A Preview of the 4th Annual Conference
3
NeurologyLive® Brain Games: September 14, 2025
4
This Week on NeurologyLive® — September 15, 2025
5